Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Mineralys Therapeutics, Inc. (MLYS) had Return on Tangible Equity of -23.91% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-154.65M |
|
-- |
|
-- |
|
$170.60M |
|
$-170.60M |
|
$15.95M |
|
$-154.65M |
|
$-154.65M |
|
$-154.65M |
|
$-154.65M |
|
$-154.65M |
|
$-154.65M |
|
$-170.60M |
|
$-170.54M |
|
67.66M |
|
67.66M |
|
$-2.29 |
|
$-2.29 |
|
| Balance Sheet Financials | |
$661.39M |
|
$0.04M |
|
$0.42M |
|
$661.81M |
|
$15.11M |
|
-- |
|
-- |
|
$15.11M |
|
$646.69M |
|
$646.69M |
|
$646.69M |
|
81.54M |
|
| Cash Flow Statement Financials | |
$-142.42M |
|
$-389.75M |
|
$591.00M |
|
$114.09M |
|
$172.92M |
|
$58.83M |
|
$19.32M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
43.76 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-142.43M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-23.91% |
|
|
Return on Tangible Equity |
-23.91% |
-23.37% |
|
-23.91% |
|
$7.93 |
|
$-2.11 |
|
$-2.10 |
|